Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Odonate Therapeutics

Odonate Therapeutics?uq=hBqTzBbB
PUBLIC STATUS
51-60 EMPLOYEES
ODT STOCK SYMBOL
$15.14 SHARE PRICE (As of Thursday Closing)
Description

Developer of oral chemotherapy drug intended to improve and extend the lives of cancer patients. The company's cancer therapeutics platform focuses on the development of tesetaxel, a novel, orally administered taxane. It is developing an effective chemotherapy choice for patients as it's in pill form and free of some side-effect-causing ingredients (polysorbet 80, polyoxyethylated castor oil), enabling them to get quality-of-life advantages over current alternatives.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 4747 Executive Drive
  • Suite 510
  • San Diego, CA 92121
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Odonate Therapeutics’s full profile, request a free trial.

Odonate Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$14.50 - $31.00 $423M $15.76 -$4.15 59.3K 26.8M

Odonate Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 344,541 669,660
Revenue 0
EBITDA (76,792) (32,724) (3,085) (158)
Net Income (75,943) (32,744) (3,085) (158)
Total Assets 166,145 203,494 2,881 140
Total Debt 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Odonate Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Odonate Therapeutics‘s full profile, request access.

Request full access to PitchBook

Odonate Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Kevin Tang Chief Executive Officer & Chairman
John Lemkey Chief Financial Officer
Robert Millham Chief Operating Officer
Joseph O'Connel MD Chief Medical Officer

Odonate Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Aaron Davis Odonate Therapeutics Director 000 0000
Craig Johnson Self Director 000 0000
George Tidmarsh Ph.D Self Director 000 0000
Jeff Vacirca MD Odonate Therapeutics Vice Chairman 000 0000
Kevin Tang Odonate Therapeutics Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 6 board members. Get the full list »